Alnylam Pharmaceuticals, Inc. (ALNY) – What Are Investment Firms Saying About This Stock?

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has received a consensus recommendation of “Moderate Buy” from the twenty-six ratings firms that are currently covering the stock, Marketbeat Ratings reports. Ten analysts have rated the stock with a hold recommendation, fifteen have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price target among analysts that have covered the stock in the last year is $305.86.

A number of analysts have recently commented on ALNY shares. Bank of America reissued a “buy” rating and set a $287.00 price target (down from $460.00) on shares of Alnylam Pharmaceuticals in a research note on Friday, October 30th. Cantor Fitzgerald restated a “neutral” rating on shares of Alnylam Pharmaceuticals in a report on Wednesday, September 30th. Citigroup lowered their target price on Alnylam Pharmaceuticals from $340.00 to $320.00 and set a “buy” rating for the company in a research report on Wednesday, October 14th. Truist Financial lowered Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating and lowered their target price for the stock from $315.00 to $225.00 in a research report on Monday, November 2nd. Finally, JPMorgan Chase & Co. cut their target price on Alnylam Pharmaceuticals from $375.00 to $369.00 and set an “overweight” rating on the stock in a report on Wednesday, September 30th.

Insider Activity at Alnylam Pharmaceuticals

In related news, EVP Bryan Supran sold 1,758 shares of the company’s stock in a transaction that occurred on Friday, October 2nd. The stock was sold at an average price of $226.88, for a total value of $398,855.04. Following the sale, the executive vice president directly owned 12,807 shares in the company, valued at $2,905,652.16. This represents a 12.07% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 0.86% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Bank of Nova Scotia increased its position in shares of Alnylam Pharmaceuticals by 0.6% during the first quarter. Bank of Nova Scotia now owns 7,798 shares of the biopharmaceutical company’s stock worth $2,580,000 after buying an additional 49 shares during the period. SBI Securities Co. Ltd. boosted its position in Alnylam Pharmaceuticals by 27.8% during the third quarter. SBI Securities Co. Ltd. now owns 225 shares of the biopharmaceutical company’s stock valued at $56,000 after acquiring an additional 49 shares during the last quarter. Prestige Wealth Management Group LLC boosted its position in Alnylam Pharmaceuticals by 30.6% during the first quarter. Prestige Wealth Management Group LLC now owns 226 shares of the biopharmaceutical company’s stock valued at $75,000 after acquiring an additional 53 shares during the last quarter. Fortitude Family Office LLC grew its holdings in Alnylam Pharmaceuticals by 10.5% during the 3rd quarter. Fortitude Family Office LLC now owns 578 shares of the biopharmaceutical company’s stock worth $143,000 after acquiring an additional 55 shares during the period. Finally, Glenmede Trust Co. NA grew its holdings in Alnylam Pharmaceuticals by 8.3% during the 1st quarter. Glenmede Trust Co. NA now owns 731 shares of the biopharmaceutical company’s stock worth $242,000 after acquiring an additional 56 shares during the period. Institutional investors and hedge funds own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Stock Down 3.2%

ALNY stock opened at $151.64 on Wednesday. The stock has a market capitalization of $20.31 billion, a P/E ratio of 7.87 and a beta of 0.42. The company has a current ratio of 2.48, a quick ratio of 2.43 and a debt-to-equity ratio of 0.18. Alnylam Pharmaceuticals has a 12 month low of $149.18 and a 12 month high of $479.79. The firm has a 50-day moving average price of $225.18 and a 200-day moving average price of $278.96.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported $16.26 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.66 by $14.60. The business had revenue of $1.46 billion during the quarter, compared to analysts’ expectations of $1.43 billion. Alnylam Pharmaceuticals had a net margin of 52.85% and a return on equity of 155.33%. The firm’s quarterly revenue was up 16.7% compared to the same quarter last year. During the same period in the prior year, the company earned $2.90 EPS. As a group, equities research analysts anticipate that Alnylam Pharmaceuticals will post 6.85 EPS for the current fiscal year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing medicines based on RNA interference (RNAi), a biological process that can reduce the production of specific disease-causing proteins. Founded in 2002 and headquartered in Cambridge, Massachusetts, the company helped advance RNAi from a scientific discovery into a therapeutic approach. Its marketed medicines include ONPATTRO (patisiran) and AMVUTTRA (vutrisiran) for hereditary transthyretin-mediated amyloidosis, GIVLAARI (givosiran) for acute hepatic porphyria, and OXLUMO (lumasiran) for primary hyperoxaluria type 1.